First AD

Second AD

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

The Role of Biomarker Testing in Metastatic and Resectable NSCLC

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Biomarker Testing In Non–Small Cell Lung Cancer

OncLive News Network®

Penn Medicine

Cancer Centers

Partner

University of Chicago Medicine Comprehensive Cancer Center

When to Conduct Molecular Testing in NSCLC

The Utility of Rapid Lung NGS for Biomarker Testing in NSCLC

The Specificity/Sensitivity of Rapid Lung NGS for Biomarker Testing in NSCLC

Treatment Planning After Biomarker Testing in NSCLC

Benefits of In-House Biomarker Testing in NSCLC

Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC

How Biomarker Testing Could Continue to Evolve in NSCLC